Related Experiment Videos
Role of thrombotic vascular risk factors in inflammatory bowel disease
1Department of Gastroenterology, University Hospital Heraklion, Greece. ktjohn@her.forthnet.gr
Insights
Inflammatory bowel disease (IBD) patients have an increased risk of thrombosis due to a hypercoagulable state. Understanding gene-environment interactions is key to predicting when IBD patients will develop blood clots.
Area of Science:
- Gastroenterology
- Hematology
- Genetics
Background:
- Thromboembolic disease is a major complication in inflammatory bowel disease (IBD), contributing significantly to patient morbidity and mortality.
- A hypercoagulable state, affecting the entire clotting system, is well-established in IBD and linked to disease pathogenesis.
Purpose of the Study:
- To explore the complex interplay of genetic and acquired risk factors contributing to the hypercoagulable state in IBD.
- To elucidate the mechanisms underlying thrombotic events in patients with inflammatory bowel disease.
Main Methods:
- Review of recent studies investigating genetic defects (e.g., Factor V Leiden, MTHFR polymorphism) and acquired factors (e.g., antiphospholipid antibodies) in IBD-associated thrombosis.
- Analysis of the role of hyperhomocysteinemia and anticoagulant factor deficiencies.
Main Results:
- Genetic factors like Factor V Leiden and C677T MTHFR polymorphism, associated with hyperhomocysteinemia, appear to influence thrombotic manifestations in IBD.
- Acquired factors, including antiphospholipid antibodies, also contribute to the thrombotic process.
- Deficiencies in anticoagulant factors show less consistent roles, with contradictory findings in IBD patients.
Conclusions:
- The development of thrombosis in IBD patients is multifactorial, resulting from complex gene-gene and gene-environment interactions.
- Identifying these interactions is crucial for understanding and potentially preventing thrombotic events in the IBD population.
Abstract:
Thromboembolic disease is a significant cause of morbidity and mortality in patients with inflammatory bowel disease (IBD). It is recognized that a hypercoagulable state exists in IBD which involves all components of the clotting system. It has been suggested that this hypercoagulable state is closely linked to the disease pathogenesis. Recent studies have shown that genetic defects such as factor V Leiden mutation and C677T methylenetetrahydrofolate reductase polymorphism associated with hyperhomocysteinemia seem to interfere in the thrombotic manifestations of IBD. Acquired factors such as antiphospholipid antibodies could also participate in the development of the thrombotic process. Deficiencies of other anticoagulant factors play a less important role in the thrombosis, and therefore it is not surprising that the results on these factors in IBD are contradictory. In conclusion the resultant gene-gene and gene-environment interactions between risk factors are the key to the understanding of why an IBD patient develops thrombosis at a specific point in time.